KMT2E

Chr 7AD

lysine methyltransferase 2E (inactive)

Also known as: HDCMC04P, MLL5, NKp44L, ODLURO, SETD5B

This gene is a member of the myeloid/lymphoid or mixed-lineage leukemia (MLL) family and encodes a protein with an N-terminal PHD zinc finger and a central SET domain. Overexpression of the protein inhibits cell cycle progression. Alternate transcriptional splice variants have been characterized. [provided by RefSeq, Jul 2008]

GeneReviewsOMIMResearchGenerating clinical summary…
LOFmechanismADLOEUF 0.061 OMIM phenotype
Clinical SummaryKMT2E
🧬
Gene-Disease Validity (ClinGen)
complex neurodevelopmental disorder · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
139 unique Pathogenic / Likely Pathogenic· 697 VUS of 1390 total submissions
💊
Clinical Trials
1 active or recruiting trial — potential therapeutic options may be available
📖
GeneReview available — KMT2E
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?
0.06LOEUF
pLI 1.000
Z-score 8.11
OE 0.01 (0.000.06)
Highly constrained

Among the most LoF-intolerant genes (~top 3%)

Missense Constraint?
1.42Z-score
OE missense 0.87 (0.820.92)
849 obs / 973.7 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.01 (0.000.06)
00.351.4
Missense OE?0.87 (0.820.92)
00.61.4
Synonymous OE?1.18
01.21.6
LoF obs/exp: 1 / 78.6Missense obs/exp: 849 / 973.7Syn Z: -2.60
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
definitiveKMT2E-related neurodevelopmental disorder/O'Donnell-Luria-Rodan syndromeLOFAD

This gene — mechanism propensity

DN
0.16100th %ile
GOF
0.1899th %ile
LOF
0.92top 5%

The highest-scoring mechanism for this gene is loss-of-function (haploinsufficiency).

LOFprediction above median · 1 literature citation · 89% of P/LP variants are LoF · LOEUF 0.06 · ClinGen HI: Sufficient evidence for dosage pathogenicity

Literature Evidence

LOFHaploinsufficiency versus gain-of-function or dominant-negative effects specific to these missense variants in KMT2E might explain this divergence in phenotype, but requires independent validation. Disruptive variants in KMT2E are an under-recognized cause of neurodevelopmental abnormalities.1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

References

  1. 1.PMID 31079897

ClinVar Variant Classifications

1390 submitted variants in ClinVar

Classification Summary

Pathogenic70
Likely Pathogenic69
VUS697
Likely Benign388
Benign86
Conflicting54
70
Pathogenic
69
Likely Pathogenic
697
VUS
388
Likely Benign
86
Benign
54
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
69
1
0
0
70
Likely Pathogenic
55
9
3
2
69
VUS
21
644
28
4
697
Likely Benign
0
67
106
215
388
Benign
1
48
22
15
86
Conflicting
54
Total1467691592361,364

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

27 pathogenic / likely-pathogenic (of 38) ClinVar copy-number / structural variants overlap KMT2E — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

KMT2E · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.